Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Medicines licensing

Gene therapy for ‘bubble boy’ syndrome on track for EU approval

Children with an extremely rare immune deficiency disease are set to have access to gene therapy, following a recommendation for approval by the European Medicines Agency (EMA).

The disease, called adenosine deaminase deficient severe combined immunodeficiency (ADA-SCID), leaves children fatally vulnerable to common infections and is informally known as “bubble boy” syndrome, as children are often confined to sterilised plastic chambers. Without treatment, children with the condition usually die in the first two years of life.

In a study involving 12 patients who received the gene therapy, called Strimvelis, all children are alive with an average follow-up period of seven years. 

There is no authorised medicine to treat ADA-SCID in the EU. Patients can receive bone marrow transplants, but this is usually only successful when the donor is a close genetic match. Some patients in Europe have received an unapproved enzyme replacement therapy on a compassionate basis, but this requires weekly infusions and long-term treatment can impair the immune system further.

A child with ADA-SCID inherits a faulty copy of a gene from both parents that makes the enzyme adenosine deaminase. This leads to a build-up of deoxyadenosine, which is toxic and destroys infection-fighting lymphocytes and causes other developmental problems.

Strimvelis, marketed by GlaxoSmithKline, takes patient’s immature bone marrow cells and replaces the faulty gene with a copy that produces functional adenosine deaminase. These cells are then injected back into the patient and can develop into the cells of the immune system and blood. This avoids the problems of a donor match seen in traditional bone marrow transplants.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20200959

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Basic Pharmacokinetics

    Basic Pharmacokinetics

    A clear and concise basic pharmacokinetics textbook. Shows how to apply the principles to achieve successful drug therapy.

    £54.00Buy now
  • Drugs in Use

    Drugs in Use

    Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.

    £43.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • European Medicines Agency headquarters

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.